A Medivation executive at the heart of the company's team that sold the company to Pfizer for $14 billion five years ago is facing allegations of insider trading.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.